- Home
- ACIW vs MDGL Comparison
ACIW vs MDGL Comparison
Compare ACIW & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIW
- MDGL
- Stock Information
- Founded
- ACIW 1975
- MDGL 2011
- Country
- ACIW United States
- MDGL United States
- Employees
- ACIW N/A
- MDGL N/A
- Industry
- ACIW EDP Services
- MDGL Biotechnology: Pharmaceutical Preparations
- Sector
- ACIW Technology
- MDGL Health Care
- Exchange
- ACIW Nasdaq
- MDGL Nasdaq
- Market Cap
- ACIW 5.1B
- MDGL 6.1B
- IPO Year
- ACIW 1995
- MDGL N/A
- Fundamental
- Price
- ACIW $44.59
- MDGL $285.73
- Analyst Decision
- ACIW Strong Buy
- MDGL Strong Buy
- Analyst Count
- ACIW 5
- MDGL 9
- Target Price
- ACIW $60.00
- MDGL $420.63
- AVG Volume (30 Days)
- ACIW 628.8K
- MDGL 291.4K
- Earning Date
- ACIW 07-31-2025
- MDGL 08-06-2025
- Dividend Yield
- ACIW N/A
- MDGL N/A
- EPS Growth
- ACIW 87.47
- MDGL N/A
- EPS
- ACIW 2.53
- MDGL N/A
- Revenue
- ACIW $1,672,834,000.00
- MDGL $317,383,000.00
- Revenue This Year
- ACIW $9.14
- MDGL $286.17
- Revenue Next Year
- ACIW $6.78
- MDGL $64.17
- P/E Ratio
- ACIW $17.50
- MDGL N/A
- Revenue Growth
- ACIW 13.11
- MDGL N/A
- 52 Week Low
- ACIW $35.99
- MDGL $200.63
- 52 Week High
- ACIW $59.71
- MDGL $377.46
- Technical
- Relative Strength Index (RSI)
- ACIW 33.45
- MDGL 48.91
- Support Level
- ACIW $44.96
- MDGL $275.00
- Resistance Level
- ACIW $47.93
- MDGL $303.45
- Average True Range (ATR)
- ACIW 0.99
- MDGL 10.81
- MACD
- ACIW -0.06
- MDGL 1.70
- Stochastic Oscillator
- ACIW 9.92
- MDGL 49.02
About ACIW ACI Worldwide Inc.
ACI Worldwide Inc develops, markets and installs a portfolio of software products focused on facilitating electronic payments. The firm also leverages its distribution network in the Americas; Europe, the Middle East, and Africa, or EMEA; and Asia-Pacific regions to sell software developed by third parties. ACI software products process payment transactions for retail banking clients, billers such as utilities and healthcare providers, and community banks and credit unions. ACI's customers are financial institutions all over the world, but majority of the revenue is generated in the United States and EMEA regions.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.